Cook GJ, Houston S, Rubens R, et al. - Detection of bone metastases in breast cancer by 18FDG PET : differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol, 1998, 16, 3375-3379. (Pubitemid 28481635)
Gnanasegaran G, Barwick T, Adamson K, et al. - Multislice SPECT/CT in benign and malignant bone disease: when the ordinary turns into the extraordinary. Semin Nucl Med, 2009, 39, 431-442.
Costelloe CM, Rohren EM, Madewell JE, et al. - Imaging bone metastases in breast cancer : techniques and recommendations for diagnosis. Lancet Oncol, 2009, 10, 606-614.
Sanal SM, Flickinger FW, Caudell MJ, et al. - Detection of bone marrow involvement in breast cancer with magnetic resonance imaging. J Clin Oncol, 1994, 12, 1415-1421. (Pubitemid 24206240)
Liu T, Cheng T, Xu W, et al. - A meta-analysis of (18)FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skeletal Radiology, 2011, 40, 523-531.
Romer W, Nomayr A, Uder M, et al. - SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med, 2006, 47, 1102-1106. (Pubitemid 47544905)
Jerusalem G, Withofs N, Rorive A, et al. - Positron emission tomography in oncology : an update. La Revue du praticien, 2007, 57, 1864-1870. (Pubitemid 350178012)
Avril N, Menzel M, Dose J, et al. - Glucose metabolism of breast cancer assessed by 18F-FDG PET : histologic and immunohistochemical tissue analysis. J Nucl Med, 2001, 42, 9-16. (Pubitemid 32104770)
Morris PG, Lynch C, Feeney JN, et al. - Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol, 2010, 28, 3154-3159.
Heusner TA, Kuemmel S, Koeninger A, et al. - Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging, 2010, 37, 1077-1086.
Puglisi F, Follador A, Minisini AM, et al. - Baseline staging tests after a new diagnosis of breast cancer : further evidence of their limited indications. Ann Oncol, 2005, 16, 263-266. (Pubitemid 40309307)
Segaert I, Mottaghy F, Ceyssens S, et al. - Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J, 2010, 16, 617-624.
Pan L, Han Y, Sun X, et al. - FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases : a meta-analysis. J Cancer Res Clin Oncol, 2010, 136, 1007-1022.
Champion L, Brain E, Giraudet AL, et al. - Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management. Cancer, 2011, 117, 1621-1629.
Eisenhauer EA, Therasse P, Bogaerts J, et al. - New response evaluation criteria in solid tumours : revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45, 228-247.
Hamaoka T, Costelloe CM, Madewell JE, et al. - Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer, 2010, 102, 651-657.
Costelloe CM, Chuang HH, Madewell JE, et al. - Cancer Response Criteria and Bone Metastases : RECIST 1.1, MDA and PERCIST. J Cancer, 2010, 1, 80-92.
J. Collignon CG, G. Jerusalem. - Assessment of Response toTherapy for Bone Metastases : Is it Still aChallenge in Oncology? PET Clinics, 2010, 5, 311-326.
De Giorgi U, Mego M, Rohren EM, et al. - 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med, 2010, 51, 1213-1218.
Grant FD, Fahey FH, Packard AB, et al. - Skeletal PET with 18F-fluoride : applying new technology to an old tracer. J Nucl Med, 2008, 49, 68-78.
Withofs N, Grayet B, Tancredi T, et al. - 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun, 2011, 32, 168-176.
Linden HM, Stekhova SA, Link JM, et al. - Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol, 2006, 24, 2793-2799. (Pubitemid 46630578)
Withofs N, Collignon J, Rorive A, et al. - Hétérogé néité des métastases osseuses du cancer du sein : cas clinique illustrant l'intérêt de combiner différentes techniques d'imagerie. Rev Med Liège, 2011, 66, 288-290.
